Filing Details

Accession Number:
0001437749-15-005080
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-03-13 19:22:08
Reporting Period:
2015-03-12
Filing Date:
2015-03-13
Accepted Time:
2015-03-13 19:22:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1386858 Hyperion Therapeutics Inc HPTX Pharmaceutical Preparations (2834) 611512713
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1554403 A Christine Nash C/O Hyperion Therapeutics, Inc.
2000 Sierra Point Parkway, Suite 400
Brisbane CA 94005
Svp & Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-03-10 10,000 $4.08 29,003 No 4 M Direct
Common Stock Disposition 2015-03-10 10,000 $35.08 19,003 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2015-03-12 10,000 $0.00 32,709 $4.08
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
22,709 2021-04-14 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 15, 2014.
  2. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions ranging in price from $35.00-35.36. The reporting person undertakes to provide Hyperion Therapeutics, any security holder of Hyperion Therapeutics or the staff of the Securities and Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in footnote (2) to this Form 4.
  3. The shares acquired upon exercise of portion of option exercised were fully vested and exercisable. The option began vesting on April 15, 2011, at a rate of 1/48th per month.